169 related articles for article (PubMed ID: 15679171)
1. Minimizing the potential for metabolic activation as an integral part of drug design.
Evans DC; Baillie TA
Curr Opin Drug Discov Devel; 2005 Jan; 8(1):44-50. PubMed ID: 15679171
[TBL] [Abstract][Full Text] [Related]
2. Minimizing metabolic activation during pharmaceutical lead optimization: progress, knowledge gaps and future directions.
Kumar S; Kassahun K; Tschirret-Guth RA; Mitra K; Baillie TA
Curr Opin Drug Discov Devel; 2008 Jan; 11(1):43-52. PubMed ID: 18175266
[TBL] [Abstract][Full Text] [Related]
3. Approaches for minimizing metabolic activation of new drug candidates in drug discovery.
Kumar S; Mitra K; Kassahun K; Baillie TA
Handb Exp Pharmacol; 2010; (196):511-44. PubMed ID: 20020275
[TBL] [Abstract][Full Text] [Related]
4. Lead optimization strategies as part of a drug metabolism environment.
Korfmacher WA
Curr Opin Drug Discov Devel; 2003 Jul; 6(4):481-5. PubMed ID: 12951811
[TBL] [Abstract][Full Text] [Related]
5. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development.
Evans DC; Watt AP; Nicoll-Griffith DA; Baillie TA
Chem Res Toxicol; 2004 Jan; 17(1):3-16. PubMed ID: 14727914
[TBL] [Abstract][Full Text] [Related]
6. Current and future trends in the application of HPLC-MS to metabolite-identification studies.
Castro-Perez JM
Drug Discov Today; 2007 Mar; 12(5-6):249-56. PubMed ID: 17331890
[TBL] [Abstract][Full Text] [Related]
7. Strategies for dealing with metabolite elucidation in drug discovery and development.
Nassar AE; Talaat RE
Drug Discov Today; 2004 Apr; 9(7):317-27. PubMed ID: 15037231
[TBL] [Abstract][Full Text] [Related]
8. Lead optimization via high-throughput molecular docking.
Joseph-McCarthy D; Baber JC; Feyfant E; Thompson DC; Humblet C
Curr Opin Drug Discov Devel; 2007 May; 10(3):264-74. PubMed ID: 17554852
[TBL] [Abstract][Full Text] [Related]
9. Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology.
Baillie TA
Chem Res Toxicol; 2006 Jul; 19(7):889-93. PubMed ID: 16841955
[TBL] [Abstract][Full Text] [Related]
10. Modeling promiscuity based on in vitro safety pharmacology profiling data.
Azzaoui K; Hamon J; Faller B; Whitebread S; Jacoby E; Bender A; Jenkins JL; Urban L
ChemMedChem; 2007 Jun; 2(6):874-80. PubMed ID: 17492703
[TBL] [Abstract][Full Text] [Related]
11. Quantitative structure-pharmacokinetics relationships and their importance in drug design, possibilities and limitations.
Seydel JK
Methods Find Exp Clin Pharmacol; 1984 Oct; 6(10):571-81. PubMed ID: 6513673
[No Abstract] [Full Text] [Related]
12. Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism.
Baillie TA
Chem Res Toxicol; 2008 Jan; 21(1):129-37. PubMed ID: 18052111
[TBL] [Abstract][Full Text] [Related]
13. [Strategy of molecular drug design: hits, leads and drug candidates].
Guo ZR
Yao Xue Xue Bao; 2008 Sep; 43(9):898-904. PubMed ID: 19048779
[TBL] [Abstract][Full Text] [Related]
14. Application of pharmaceutical profiling assays for optimization of drug-like properties.
Di L; Kerns EH
Curr Opin Drug Discov Devel; 2005 Jul; 8(4):495-504. PubMed ID: 16022186
[TBL] [Abstract][Full Text] [Related]
15. Drug metabolism: an industrial research view of the future.
Ober RE
Drug Metab Rev; 1979; 10(2):315-9. PubMed ID: 551917
[No Abstract] [Full Text] [Related]
16. Addressing metabolic activation as an integral component of drug design.
Doss GA; Baillie TA
Drug Metab Rev; 2006; 38(4):641-9. PubMed ID: 17145693
[TBL] [Abstract][Full Text] [Related]
17. Monitoring drug-protein interaction.
Yang XX; Hu ZP; Chan SY; Zhou SF
Clin Chim Acta; 2006 Mar; 365(1-2):9-29. PubMed ID: 16199025
[TBL] [Abstract][Full Text] [Related]
18. The future of drug safety testing: expanding the view and narrowing the focus.
Stevens JL; Baker TK
Drug Discov Today; 2009 Feb; 14(3-4):162-7. PubMed ID: 19100337
[TBL] [Abstract][Full Text] [Related]
19. Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability.
Nassar AE; Kamel AM; Clarimont C
Drug Discov Today; 2004 Dec; 9(23):1020-8. PubMed ID: 15574318
[TBL] [Abstract][Full Text] [Related]
20. The Scheele memorial lecture 1989. Drug metabolism in the design and safety evaluation of new drugs.
Parke DV
Acta Pharm Nord; 1990; 2(4):231-48. PubMed ID: 2257083
[No Abstract] [Full Text] [Related]
[Next] [New Search]
